- [PRESSWIRE] US – 05.05.25 — Join the L2 Bio® Stem Cell Revolution. L2 Bio® currently has over 50 Stem Cell Centers across the USA and is thrilled to announce the official launch of the L2 300 Expansion Initiative which has secured the funding necessary to open 300 additional Stem Cell Centers of Excellence over the next 12 months.
- [PRESSWIRE] NY, US – 25.04.25 — Dr. Ken Moadel, New York’s most trusted name in eye care for over 30 years, is now available in 4 NYC boroughs.
- Unique Service to Link Consumers with Physicians for Written Opinions on Potential Negligence
- Veterinary professionals take an oath to benefit society first, then animals. But are they prepared to benefit an ever-diverse society of animal owners?
- [PRESSWIRE] France – 12.12.24 — Clermont-Ferrand, France, December 12th, 2024 – Sepul Bio, an innovative business unit of Laboratoires Théa (“Théa”)dedicated to the advancement of RNA therapies for inherited retinal diseases, has today announced the first clinical participant has been dosed in LUNA clinical study, a Phase 2b clinical study for ultevursen, in individuals with retinitis pigmentosa (RP) or non-syndromic RP due to variants in exon 13 of the Usher Syndrome Type 2a gene.
- [PRESSWIRE] London, UK – 07.11.24 — Thirty years after treatment for chronic asthma and psoriasis Stephanie remains symptom free.
- New Nikon BioImaging Labs opening, providing solutions to your assay development, microscope-based imaging and image analysis needs…
- A groundbreaking real-world study involving over 9,000 adults with type 1 diabetes has uncovered important differences between males and females in insulin requirements…
- [PRESSWIRE] AMSTERDAM, THE NETHERLANDS – 04 July, 2024 — Nikon Europe B.V. (Nikon) will launch the ECLIPSE Ti2-I Motorized Inverted Microscope for ICSI*3/IMSI*4, specialized for use in micro-insemination, from July 5. By allowing the microscope settings to be automatically controlled via simple buttons and a touch screen close to your hands – we’ve improved efficiency by reducing the steps required for operation by approximately 75%. An alert function and bright, clear field of view support accurate operation.
- [PRESSWIRE] Nottingham, UK – June 4th, 2024 — 4D Medicine Limited has appointed Dr Tom Buckland as its new Chairman and Non-executive Director.
- [PRESSWIRE] IRELAND – 14 May, 2024 — A group of the world’s leading experts in the treatment of stroke are calling on the EU to make sweeping changes to regulations governing the development of medical devices, adding that the current rules are inhibiting innovation and preventing patients from accessing life-saving care.
- [PRESSWIRE] Puerto Rico – 12.02.24 — Renowned chiropractic doctor and author, Dr. Cesia Estebané, is thrilled to announce the release of the English version of her book, “The Doctor in You: 5 Constructs to Discover Your Innate Power to Heal.”
- [PRESSWIRE] Dubai, UAE – 30.01.24 — Open Medical Europe, a leading provider of healthcare digital transformation solutions, is excited to announce a groundbreaking collaboration with the Ministry of Health (MOH) in the Kingdom of Saudi Arabia, and Farouk, Maamoun Tamer & Co. (Tamer) from Saudi Arabia.
- [PRESSWIRE] Zürich – 12.1.2024 — Smart Blood Analytics Swiss, a pioneering leader in healthcare technology in the segment of blood test result interpretation, proudly announces that its groundbreaking product, SBAS Software, achieved the first EU-MDR (European Medical Device Regulation) certification1 as a medical device using cutting-edge AI technology for blood test result interpretation. Based on the European Database of Medical Devices, this achievement marks a significant milestone, positioning Smart Blood Analytics Swiss among only 10 AI medical device companies recognized with the prestigious EU-MDR certification to date2.
- [PRESSWIRE] US – 26.12.23 — Breaking Ground in Shingles Treatment: Wintermute Biomedical Advances to Clinical Trials … Wintermute Biomedical is excited to report that in December 2023 they have received full approval to conduct a Phase IB clinical trial in Australia using their first-in-class topical antiviral, Solexan. Solexan has been developed over the last 12 years by Wintermute Biomedical as a novel topical antiviral for herpes viruses including shingles, herpes simplex 1 (cold sores) and herpes simplex 2 (genital herpes).
- [PRESSWIRE] London, UK – 17.11.23 — Cannatrona, a specialist in the design and manufacture of advanced filter tips and mouthpieces for the cannabis and hemp sectors, will make its debut at MJBizCon 2023 and introduce its new products at booth 1827 from 28 November to 1 December 2023.
- [PRESSWIRE] Tampa, FL – 11/08/2023 – Vein911® Vein Treatment Centers welcomes the additions of Drs. Brian Pink and Arian Moshref to their award-winning, world-renowned vein care specialist team. They join the mutli-location practice founded by Dr. Chris Pittman to better serve Tampa Bay residents suffering from varicose veins, swelling, skin changes, ulcers, restless legs, night cramps, leg discomfort, cosmetic spider veins and bulging hand veins.
- [PRESSWIRE] South Lake Tahoe, CA – 30.10.23 — An online platform that seeks to drive awareness of the positive aspects of the Herbal Lifestyle has gone from strength to strength since it opened in early 2023. Body: Patientopia’s online Community Smoke Shop is rapidly becoming a leader in the industry thanks to having some of the best products in the market available today to enable newcomers to either try the herbal approach or for veterans of the scene to engage.
- [PRESSWIRE] London, UK – 26.10.23 — More than half of UK adults are self-diagnosing their health problems online rather than seeing a medical professional (55% of adults in the past 6 months).
- [PRESSWIRE] Belgium – 18.09.23 — AbolerIS Pharma (“AbolerIS”), a biopharmaceutical company developing an entirely novel approach to the treatment of chronic autoimmune and inflammatory diseases, today announced a €27.3 million Series A financing led by Caixa Capital Risc and co-led by Sound Bioventures and existing investor Newton Biocapital with participation from SFPI-FPIM, WE, Sambrinvest, Investsud Tech, and Relyens Innovation Santé/Turenne Capital. Proceeds from the financing will enable AbolerIS to accelerate the development of its lead program in clinical trials and explore its effectiveness in additional autoimmune diseases.
- [PRESSWIRE] Czech Republic – 13.09.23 — On the 5th World Gynecologic Oncology Day, patient advocates around the globe will unite to raise awareness about the importance of testing for gynecologic cancers and their risk factors. World GO Day is a unique opportunity to educate people worldwide about the importance of sharing information about symptoms, treatment, prevention and, especially, testing.
- [PRESSWIRE] US – 08.09.23 — At-the-Market fundraise to support Company through several potentially value-creating milestones and beyond…
- [PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – September 8, 2023 – ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that Gail Farfel, Ph.D., Chief Executive Officer and Larry Altstiel, M.D., Ph.D., Chief Medical Officer of ProMIS Neurosciences, will present at the upcoming H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023 at 4:30 p.m. ET in New York, NY.
- [PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – September 6, 2023 – ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that Gail Farfel, Ph.D., Chief Executive Officer and Larry Altstiel, M.D., Ph.D., Chief Medical Officer of ProMIS Neurosciences, will present at the upcoming H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023 at 4:30 p.m. ET in New York, NY.
- [PRESSWIRE] London, UK – 06.09.23 — New research from tech consulting and engineering firm Zühlke reveals that there is huge unmet demand for prescription apps from the NHS across the whole UK population – particularly for prevention of high-volume illnesses where the NHS is struggling to cope with demand, such as depression, anxiety, obesity & diabetes, and cancer.
- [PRESSWIRE] Switzerland – 31.08.23 — greenteg’s CALERA® technology provides temperature tracking in new generation hybrid, health-monitoring wristwatch.
- [PRESSWIRE] Itagüí, Antioquia, Colombia – 30.08.23 — Efraín Antonio Ríos García, a la edad de 113 años y 133 días, se convirtió en el hombre más longevo en toda la historia de Colombia el pasado 15 de agosto. Él ha sido la persona viva más longeva en Colombia después del fallecimiento del Sr. Eusebio Quintero López el 16 de julio de 2023. Según la lista mundial de LongeviQuest, el Sr. Ríos García es la decimocuarta persona viva más longeva en el mundo. Además, es la sexta persona viva más longeva en América.
- [PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – May 15, 2023 – ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced its first quarter 2023 financial results and recent highlights.
- [PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – May 8, 2023 – ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for PMN310 for the treatment of AD. PMN310 is a novel monoclonal antibody which is designed to be highly selective for toxic oligomers of amyloid-beta (Aβ) that are believed to be a major driver of AD.
- [PRESSWIRE] Luxembourg – 04.05.23 — B Medical Systems India Pvt Ltd, a subsidiary of B Medical Systems, today announced the inauguration of its state-of-the-art Global R&D and Customer Excellence Centre in Mumbai. The Centre was inaugurated by Shri Gajanan Kirtikar, a Member of Parliament (MP) from Mumbai North West (Lok Sabha constituency), Maharashtra, India and the event was attended by numerous other dignitaries.
